Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
September, 2026
September 2026
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
Isabelle Mahé on Reduced Dose Apixaban and Cancer-Associated VTE
Isabelle Mahé /LinkedIn
Jan 15, 2026, 12:18

Isabelle Mahé on Reduced Dose Apixaban and Cancer-Associated VTE

Isabelle Mahé, Head of Internal Medicine, Louis Mourier Hospital, APHP, Paris Cité University, shared on LinkedIn:

”Just published in the Lancet Haematology
In this post-hoc analysis of the API-CAT Study, including patients with CAT receiving extended anticoagulant with apixaban.

  • 4 clinical predictors were significantly associated with increased CRB risk : anaemia and/or thrombocytopenia, age ≥75, PE as the index event, and male sex.
  • 3 of them are also significant predictors of MB
  • Identified predictors are non modifiable
  • No cancer-related predictors associated with increased CRB risk
  • Associations are consistent across cancer sites
  • No evidence of interaction with apixaban dose

To reach the publication.
To reach the Comment.

As a reminder, in CAT extended treatment NEJM

Reduced dose apixaban is non inferior to full-dose on VTE recurrence, and associated with a 25% reduction in the risk of CRB

To reach the publication: Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism. DOI 10.1056/NEJMoa2416112”

Read the full article here.

Article: Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism

Authors: Isabelle Mahé, Marc Carrier, Didier Mayeur, Jean Chidiac, Eric Vicaut, Nicolas Falvo, Olivier Sanchez et al.

Isabelle Mahé on Reduced Dose Apixaban and Cancer-Associated VTE

Stay updated on all scientific advances with Hemostasis Today.

API-CAT Apixaban cancer CAT Health Hematology Hemostasis Hemostasis News Hemostasis Today Isabelle Mahé Lancet Haematology Medicine NEJM OncoDaily thrombosis VTE
NewsFeed